ArticleThe journal of prevention of Alzheimer's disease2026
Oxidation over omega-3: Reinterpreting the paradoxical link between fish oil supplements and accelerated cognitive decline.
Article in The journal of prevention of Alzheimer's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liao et al. (2026) recently reported an association between omega-3 supplementation and accelerated cognitive decline, mediated by FDG-PET hypometabolism. While clinically provocative, this observational finding warrants cautious interpretation. This Letter critiques four methodological limitations: (1) exposure misclassification, as ADNI's binary supplement variable ignores oxidation state and formulation (pharmacy grade vs. oxidized OTC fish oil); (2) residual confounding, since propensity score matching cannot adjust for subtle preclinical worry or lifestyle factors driving supplement initiation; (3) mechanistic overreach, as FDG hypometabolism reflects composite metabolic/inflammatory processes, not isolated synaptic dysfunction; and (4) context dependency, where effects likely hinge on baseline omega-3 status and individual oxidative load. We propose actionable refinements: biomarker-anchored dose modeling (serum EPA+DHA), negative-control sensitivity analyses, partial volume-corrected FDG mediation, and CSF synaptic marker integration. Rather than a universal "harm" signal, this paradoxical association should be framed as hypothesis generating, urging personalized prevention strategies over blanket clinical warnings.To the Editor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.